Coca-Cola recalled 2,000 cases of drinks due to potential contamination

Cans of Sprite and Fanta, beverages produced by the Coca-Cola Company, seen displayed in a supermarket.

Alex Tai | Lightrocket | Getty Images

The Food and Drug Administration disclosed the recall in a filing and said it began on Nov. 6. It encompasses 1,557 cases of 12-ounce cans of Sprite, 417 cases of Diet Coke, and 14 cases of Fanta Orange.

The FDA filing shows the recall started Nov. 6, and it was made by United Packers, based in Alabama.

In an email to NBC News, Coca-Cola Co. said the recall is complete and there are no more affected cans on the market.

Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to billion

Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

January 21, 2026

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

January 20, 2026

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

January 20, 2026

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]